SAN FRANCISCO, Oct. 10, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology
company focused on developing and commercializing gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced the pricing of its underwritten public
offering of 5,200,000 shares of its common stock at a price to the
public of $29.00 per share. The
gross proceeds to Audentes from the offering, before deducting the
underwriting discounts and commissions and other offering expenses
payable by Audentes, are expected to be $150.8 million. The offering is expected to
close on October 15, 2018, subject to
customary closing conditions. In addition, Audentes has
granted the underwriters a 30-day option to purchase up to an
additional 780,000 shares of common stock.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen are
acting as joint book-running managers for the offering.
Wedbush PacGrow is acting as co-manager.
The public offering is being made pursuant to a shelf
registration statement (File No. 333-224020) on Form S-3 that was
filed by Audentes with the Securities and Exchange Commission
("SEC") on March 29, 2018 and that
automatically became effective upon filing. A final
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the
SEC's website at www.sec.gov. Alternatively, a copy of the
final prospectus supplement relating to the offering, when
available, may be obtained from BofA Merrill Lynch, NC1-004-03-43,
200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department, or by email at
dg.prospectus_requests@baml.com; J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY, 11717, Attention:
Prospectus Department, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and other federal securities laws. Any statements
contained herein that do not describe historical facts, including,
but not limited to, statements regarding the expected gross
proceeds and completion of the offering, are forward-looking
statements that involve risks and uncertainties that could cause
actual results to differ materially from those discussed in such
forward-looking statements. Such risks and uncertainties
include, among others, the risks identified in Audentes' filings
with the SEC, the prospectus related to the offering, and
subsequent filings with the SEC. Any of these risks and
uncertainties could materially and adversely affect Audentes'
results of operations, which would, in turn, have a significant and
adverse impact on Audentes' stock price. Audentes cautions
you not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. Audentes
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date they were made or to reflect the occurrence of
unanticipated events.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-pricing-of-public-offering-of-common-stock-300729122.html
SOURCE Audentes Therapeutics, Inc.